Skip to main content

Advertisement

Table 2 Factors associated with progression-free survival (PFS) by univariate and multivariate analysis

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

PFS univariate analysis multivariate analysis
Variables HR [95%CI] p HR [95%CI] p
11q deletion (n = 153)
 No (ref) 1.00   1.00  
 Yes 2.19 [1.35; 3.56] 0.0012 1.74 [0.94; 3.21] 0.076
IGHV mutation status (n = 131)
 Mutated (ref) 1.00   1.00  
 Unmutated 2.55 [1.42; 4.59] 0.0012 2.03 [1.02; 4.04] 0.043
EOT MRDa (n = 131)
 Low (ref) 1.00   1.00  
 Intermediate 2.64 [1.55; 4.50]   2.43 [1.39; 4.27] 0.002
 High 6.95 [3.24; 14.92] < 0.0001 4.56 [1.76;11.79] 0.002
EOT CD4a (/mm3, n = 132)
  ≤ 200 (ref) 1.00   1.00  
  > 200 2.28 [1.35; 3.86] 0.0016 3.30 [1.79; 6.06] < 0.001
EOT NKa (/mm3, n = 109)
  ≤ 100 (ref) 1.00  
  > 100 1.03 [0.60; 1.78] 0.9101   
EOT CD8a (/mm3, n = 132)
  ≤ 150 (ref) 1.00  
  > 150 1.02 [0.62; 1.66] 0.9418   
EOT monocytesa (/mm3, n = 114)
  ≤ 400 (ref) 1.00  
  > 400 1.30 [0.77; 2.19] 0.3257   
  1. aindicates Landmark analysis at 9 months